Directed new share issue in Calliditas Therapeutics (SE) — SEK 210 million

Carnegie acted as adviser and joint bookrunner in the directed new share issue of 3.5 million new shares at a subscription price at SEK 60 per share. In connection with the Issue, some of the Company’s larger shareholders – Industrifonden, Investinor and Bengt Julander – sold approximately 1.5 million shares and furthermore BVF acquired call options from Industrifonden, Investinor and Mikael Bender (BVF will hold approximately 3 million shares in the Company if the option is exercised). Calliditas is a specialty pharmaceutical company based in Stockholm, Sweden, focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications in which Calliditas can partially or completely participate in the commercialization efforts. July 2019.